Tina Gerbek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tina Gerbek has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Birthe Lykke Thomsen
Department of Pediatrics and Adolescent Medicine University Hospital of Copenhagen Copenhagen Denmark
1 shared publicationEna Muhic
Department of Pediatrics and Adolescent Medicine University Hospital of Copenhagen Copenhagen Denmark
1 shared publication- Jacob Nersting
Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark
1 shared publication Kaspar Sørensen
Department of Pediatrics and Adolescent Medicine University Hospital of Copenhagen Copenhagen Denmark
1 shared publication- Kjeld Schmiegelow
Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Copenhagen, Denmark
1 shared publication Klaus Kofoed
Department of Cardiology, The Heart Center, Rigshospitalet University of Copenhagen Copenhagen Denmark
1 shared publication
Latest Publications
- Open Access
- 17 April 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (4) , e14530
Metabolic syndrome as a late effect of childhood hematopoietic stem cell transplantation – A thorough statistical evaluation of putative risk factors
Background: Metabolic syndrome (MetS) is frequent among survivors of childhood hematopoietic stem‐cell transplantation (HSCT), but assessment of risk factors is challenged by survivor and participation bias in long‐term follow‐up studies.Methods: A cohort of 395 pediatric patients transplanted between 1980 and 2018 was investigated. MetS was assessed at follow‐up between December 2018 and March 2020. Two composite outcomes ((a) combining MetS and death, (b) combining MetS, death, and nonparticipation) were considered to address the risk of selection bias.Results: Among 234 survivors invited to the follow‐up, 96 individuals (median age 27 years) participated. MetS prevalence was 30% among participants. The only significant HSCT risk factor was a variable combining HSCT indication and conditioning with total‐body irradiation (TBI) (p = .0011). Compared to acute leukemias (AL) treated with high‐grade TBI (8–12 Gy), a lower MetS prevalence was seen for nonmalignant diseases treated with no/low‐grade TBI (0–4.5 Gy) (OR = 0.04, 95% confidence interval (CI): 0.00–0.23). Analyses of the composite outcomes indicated overestimation of the effect of high‐grade TBI due to selection bias. Scrutiny showed strong residual confounding between HSCT indication and high‐grade TBI within AL‐patients. The HSCT effect on MetS reflected HSCT effects on high‐density‐lipoprotein (HDL) and triglycerides. Compared to AL treated with high‐grade TBI, nonmalignant diagnoses treated with no/low‐grade TBI had higher HDL (+40%, 95% CI: +21% to +62%) and lower triglyceride (−59%, 95% CI: −71% to −42%).Conclusion: The TBI effect on MetS may be overestimated in follow‐up studies due to selection bias and confounding. The TBI effect was confined to the potentially modifiable MetS criteria HDL and triglyceride.
- 17 April 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (4) , e14530
Open AccessMetabolic syndrome as a late effect of childhood hematopoietic stem cell transplantation – A thorough statistical evaluation of putative risk factors
Background: Metabolic syndrome (MetS) is frequent among survivors of childhood hematopoietic stem‐cell transplantation (HSCT), but assessment of risk factors is challenged by survivor and participation bias in long‐term follow‐up studies.Methods: A cohort of 395 pediatric patients transplanted between 1980 and 2018 was investigated. MetS was assessed at follow‐up between December 2018 and March 2020. Two composite outcomes ((a) combining MetS and death, (b) combining MetS, death, and nonparticipation) were considered to address the risk of selection bias.Results: Among 234 survivors invited to the follow‐up, 96 individuals (median age 27 years) participated. MetS prevalence was 30% among participants. The only significant HSCT risk factor was a variable combining HSCT indication and conditioning with total‐body irradiation (TBI) (p = .0011). Compared to acute leukemias (AL) treated with high‐grade TBI (8–12 Gy), a lower MetS prevalence was seen for nonmalignant diseases treated with no/low‐grade TBI (0–4.5 Gy) (OR = 0.04, 95% confidence interval (CI): 0.00–0.23). Analyses of the composite outcomes indicated overestimation of the effect of high‐grade TBI due to selection bias. Scrutiny showed strong residual confounding between HSCT indication and high‐grade TBI within AL‐patients. The HSCT effect on MetS reflected HSCT effects on high‐density‐lipoprotein (HDL) and triglycerides. Compared to AL treated with high‐grade TBI, nonmalignant diagnoses treated with no/low‐grade TBI had higher HDL (+40%, 95% CI: +21% to +62%) and lower triglyceride (−59%, 95% CI: −71% to −42%).Conclusion: The TBI effect on MetS may be overestimated in follow‐up studies due to selection bias and confounding. The TBI effect was confined to the potentially modifiable MetS criteria HDL and triglyceride.
- 1 February 2018
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 81 (3) , 579-586
Role of TPMT and ITPA variants in mercaptopurine disposition
To explore the levels of thioguanine incorporated into DNA (DNA-TG), and erythrocyte levels of 6-thioguanine nucleotides (Ery-TGN) and methylated metabolites (Ery-MeMP) during 6-mercaptopurine (6MP)/Methotrexate (MTX) therapy of childhood acute lymphoblastic leukemia (ALL) and the relation to inosine triphosphatase (ITPA) and thiopurine methyltransferase (TPMT) gene variants.
- 1 February 2018
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 81 (3) , 579-586
Role of TPMT and ITPA variants in mercaptopurine disposition
To explore the levels of thioguanine incorporated into DNA (DNA-TG), and erythrocyte levels of 6-thioguanine nucleotides (Ery-TGN) and methylated metabolites (Ery-MeMP) during 6-mercaptopurine (6MP)/Methotrexate (MTX) therapy of childhood acute lymphoblastic leukemia (ALL) and the relation to inosine triphosphatase (ITPA) and thiopurine methyltransferase (TPMT) gene variants.